Label and animal imaging studies of prostate specific membrane antigen molecular image probe 68Ga-PSMA11?

Ji ZHANG,Xiaoping XU,Cheng LIU,Jianping ZHANG,Jianmin LUO,Chang LIU,Silong HU,Shaoli SONG,Yingjian ZHANG
DOI: https://doi.org/10.19732/j.cnki.2096-6210.2019.04.001
2019-01-01
Abstract:Objective: Prostate specific membrane antigen (PSMA) plays an important role in diagnosis of prostate cancer. In this study, researchers labeled a new type PSMA inhibitor PSMA11 with 68Ga, did quality control (QC) according to Chinese Pharmacopoeia, and investigated pharmaceutical effect in prostate cancer animal models. Methods: Positron molecular probe 68Ga-PSMA11 prepared by PSMA11 precursor labeling with 68Ga, which was eluted from 68Ge/68Ga generator. Quality criterion according to standard of pharmacopoeia was established for QC of 68Ga-PSMA11. And the probe was injected into mice of LNCaP xenograft model for dynamic imaging by small animal PET/CT. Results: 68Ga-PSMA11 was successfully prepared, and QC was in compliance with quality criterion. Radiochemical purity was greater than 99%. The probe was combined with tumor specifically, besides physiological distribution in kidneys and bladder. Conclusion: 68Ga-PSMA11 was easy to label and had high intake in tumor. It is a promising positron molecular probe targeting PSMA.
What problem does this paper attempt to address?